Key Highlights

  • Net loss per share was USD 1.29, against an estimate of a USD 0.39 loss.
  • Net loss was USD 5.06 million, versus Net Income of USD 4.68 million.
  • Collaboration and license Revenue was USD 361,802, versus USD 8.85 million.
  • Cash was USD 3.74 million at September 30, 2026.

Palatin Technologies (NASDAQ:PTN) swung to a loss in the first quarter of fiscal 2027, which ended September 30, 2026. The net loss was USD 5.06 million, compared with net income of USD 4.68 million a year earlier. Basic and diluted net loss per share was USD 1.29, compared with basic net income per share of USD 4.81 and diluted net income per share of USD 4.26, against an estimate of a USD 0.39 loss.

Palatin is a biopharmaceutical company building first in class medicines from peptide and small molecule compounds that act on the melanocortin receptor system.

What Changed From a Year Ago

Collaboration and license revenue was USD 361,802, compared with USD 8.85 million. Research and Development expense was USD 3.38 million, compared with USD 2.53 million, and general and administrative expense was USD 2.08 million, compared with USD 1.66 million. Total operating expenses were USD 5.46 million, compared with USD 4.19 million, so the company posted a loss from operations of USD 5.10 million, compared with income from operations of USD 4.66 million.

Investment income was USD 46,534, compared with USD 18,483, and interest expense was USD 1,690, compared with USD 2,002. Weighted average shares outstanding used for basic per-share figures were 3,922,464, compared with 971,650.

Balance Sheet Snapshot

Cash and cash equivalents were USD 3.74 million at September 30, 2026, compared with USD 7.49 million at June 30, 2026. Accounts Receivable were USD 361,802, compared with USD 300,770, and total Assets were USD 4.72 million, compared with USD 8.52 million.

Total liabilities were USD 2.69 million, compared with USD 1.84 million, and current liabilities were USD 2.66 million, compared with USD 1.77 million. Accrued expenses were USD 1.17 million, compared with USD 504 thousand. Stockholders' Equity was USD 2.03 million, compared with USD 6.69 million, and the accumulated Deficit was USD 472.51 million, compared with USD 467.45 million.

Net cash used in financing activities was USD 10,001, compared with net cash provided of USD 328,200 a year earlier. The cover page reports 1,780,939 shares of common stock outstanding as of November 13, 2026.

Going Concern Disclosure

Based on cash and cash equivalents at September 30, 2026, management concluded that substantial doubt exists over Going Concern status for one year after the financial statements were issued. The company says it is evaluating ways to raise more funding, including equity financing, issuing Debt or cutting planned expenses.